{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:32:43Z","timestamp":1793323963224,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI039671"],"award-info":[{"award-number":["P01AI039671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI056299"],"award-info":[{"award-number":["P01AI056299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA236749"],"award-info":[{"award-number":["P01CA236749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI144166"],"award-info":[{"award-number":["R01AI144166"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI176341"],"award-info":[{"award-number":["R01AI176341"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA187975"],"award-info":[{"award-number":["R01CA187975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA229400"],"award-info":[{"award-number":["R01CA229400"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA246653"],"award-info":[{"award-number":["R01CA246653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA282749"],"award-info":[{"award-number":["R01CA282749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["824733"],"award-info":[{"award-number":["824733"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["926682"],"award-info":[{"award-number":["926682"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["3100030_197590"],"award-info":[{"award-number":["3100030_197590"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.immuni.2024.01.010","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T10:33:47Z","timestamp":1707820427000},"page":"206-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":298,"title":["LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation"],"prefix":"10.1016","volume":"57","author":[{"given":"Nicole","family":"Joller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-2932","authenticated-orcid":false,"given":"Ana C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2024.01.010_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.010_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib4","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","article-title":"Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8\u00a0T Cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8+ T\u00a0cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T\u00a0cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01344","article-title":"Common features of regulatory T\u00a0cell specialization during Th1 responses","volume":"9","author":"Littringer","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah4569","article-title":"LAG3 limits regulatory T\u00a0cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.010_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.010_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T\u00a0cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4\u00a0+ T\u00a0cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib18","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib19","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1074\/jbc.RA119.007455","article-title":"Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T\u00a0cell activation","volume":"294","author":"Maeda","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2024.01.010_bib20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.immuni.2024.01.010_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc2728","article-title":"Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding","volume":"5","author":"Andrews","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/CBM-181278","article-title":"Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-\u03b3 in peripheral blood","volume":"23","author":"Li","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.immuni.2024.01.010_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41590-022-01238-7","article-title":"LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition","volume":"23","author":"Ming","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T\u00a0cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4049\/immunohorizons.1800083","article-title":"IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors","volume":"3","author":"DeLong","year":"2019","journal-title":"Immunohorizons"},{"key":"10.1016\/j.immuni.2024.01.010_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf5107","article-title":"LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade","volume":"13","author":"Shen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Jing","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.010_bib28","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","article-title":"Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy","volume":"28","author":"Andrews","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.010_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib30","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.immuni.2024.01.010_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor\u2013Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non\u2013Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.immuni.2024.01.010_bib32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","article-title":"B-cell-specific checkpoint molecules that regulate anti-tumour immunity","volume":"619","author":"Bod","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","article-title":"Granzyme B and perforin are important for regulatory T\u00a0cell-mediated suppression of tumor clearance","volume":"27","author":"Cao","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35754-0","article-title":"High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3","volume":"8","author":"Gandhi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.immuni.2024.01.010_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1385690","article-title":"Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy","volume":"7","author":"Sabatos-Peyton","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.immuni.2024.01.010_bib39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aba0717","article-title":"The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse","volume":"14","author":"Kataoka","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.immuni.2024.01.010_bib41","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T\u00a0cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1128\/MCB.01983-06","article-title":"PAG-Associated FynT Regulates Calcium Signaling and Promotes Anergy in T Lymphocytes","volume":"27","author":"Davidson","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.immuni.2024.01.010_bib44","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/eji.1830250707","article-title":"Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A","volume":"25","author":"Gajewski","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib45","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.immuni.2024.01.010_bib46","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41423-020-00575-7","article-title":"Opposing regulatory functions of the TIM3 (HAVCR2) signalosome in primary effector T\u00a0cells as revealed by quantitative interactomics","volume":"18","author":"Zhai","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"7865","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm0631","article-title":"Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib49","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/eji.200939274","article-title":"TIM-3 is expressed on activated human CD4+ T\u00a0cells and regulates Th1 and Th17 cytokines","volume":"39","author":"Hastings","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clim.2009.09.012","article-title":"Involvement of T\u00a0cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease","volume":"134","author":"Li","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni987","article-title":"Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance","volume":"4","author":"S\u00e1nchez-Fueyo","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib52","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1084\/jem.20060210","article-title":"Dysregulated T\u00a0cell expression of TIM3 in multiple sclerosis","volume":"203","author":"Koguchi","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib53","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.4049\/jimmunol.180.7.4409","article-title":"Lack of TIM-3 immunoregulation in multiple sclerosis","volume":"180","author":"Yang","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clim.2012.09.001","article-title":"Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T\u00a0cell function in ulcerative colitis","volume":"145","author":"Shi","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clim.2010.07.012","article-title":"Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity","volume":"137","author":"Liu","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2340\/00015555-1285","article-title":"Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis","volume":"92","author":"Kanai","year":"2012","journal-title":"Acta Derm. Venerol."},{"key":"10.1016\/j.immuni.2024.01.010_bib57","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T\u00a0cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The Immunobiology of Interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib59","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib60","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T\u00a0cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib61","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ regulatory T\u00a0cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.immuni.2024.01.010_bib62","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI45138","article-title":"Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs","volume":"122","author":"Gupta","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.01.010_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109699","article-title":"Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment","volume":"36","author":"Banerjee","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.010_bib64","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T\u00a0cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib65","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T\u00a0cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib66","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T\u00a0cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib67","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.010_bib68","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.01.010_bib69","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection","volume":"7","author":"Nebbia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2024.01.010_bib71","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T\u00a0cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.010_bib72","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.010_bib73","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T\u00a0cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.immuni.2024.01.010_bib74","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.immuni.2024.01.010_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb9726","article-title":"T cell factor 1: A master regulator of the T\u00a0cell response in disease","volume":"5","author":"Escobar","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib76","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.celrep.2018.01.072","article-title":"Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8\u00a0T Cell Differentiation","volume":"22","author":"Danilo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.010_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T\u00a0cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib78","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4049\/jimmunol.173.2.1158","article-title":"Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation","volume":"173","author":"Tunyaplin","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib79","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4049\/jimmunol.1900581","article-title":"Cutting Edge: Tcf1 instructs T follicular helper cell differentiation by repressing Blimp1 in response to acute viral infection","volume":"203","author":"Shao","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib80","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"de Mingo Pulido","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib81","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.4049\/jimmunol.1202661","article-title":"T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response","volume":"190","author":"Yang","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1189\/jlb.1010591","article-title":"Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes","volume":"91","author":"Zhang","year":"2012","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.immuni.2024.01.010_bib83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.leukres.2014.03.018","article-title":"Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis","volume":"38","author":"Tao","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.immuni.2024.01.010_bib84","article-title":"Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome","volume":"14","author":"Tcvetkov","year":"2020","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.immuni.2024.01.010_bib85","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.immuni.2024.01.010_bib86","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.010_bib93","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136855","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study","volume":"136","author":"Brunner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.010_bib94","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S2152-2650(20)30728-X","article-title":"AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study","volume":"20","author":"Brunner","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.immuni.2024.01.010_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","article-title":"Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)","volume":"40","author":"Falchook","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.immuni.2024.01.010_bib96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T\u00a0cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib97","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.200839116","article-title":"A novel molecular interaction for the adhesion of follicular CD4 T\u00a0cells to follicular DC","volume":"39","author":"Boles","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib98","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.010_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107892","article-title":"Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation","volume":"32","author":"Xiao","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.010_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156254","article-title":"Impaired TIGIT expression on B cells drives circulating follicular helper T\u00a0cell expansion in multiple sclerosis","volume":"132","author":"Asashima","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.01.010_bib100","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20222005","article-title":"TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy","volume":"220","author":"Yamada","year":"2023","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib101","article-title":"TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"Brauneck","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.010_bib102","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib103","article-title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","volume":"8","author":"Reches","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.010_bib104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2023.07.058","article-title":"Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy","volume":"677","author":"Ganguli","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.immuni.2024.01.010_bib105","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting Edge: TIGIT has T\u00a0cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib106","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/eji.201041136","article-title":"Vstm3 is a member of the CD28 family and an important modulator of T-cell function","volume":"41","author":"Levin","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib107","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.immuni.2024.01.010_bib108","doi-asserted-by":"crossref","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2024.01.010_bib109","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/eji.201243072","article-title":"Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR","volume":"43","author":"Stanietsky","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T\u00a0cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib111","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 Axis Regulates Human T Cell Function","volume":"188","author":"Lozano","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib112","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8(+) T Cell Effector Function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2024.01.010_bib88","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib113","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood-2013-02-481788","article-title":"Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T\u00a0cells","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.010_bib114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.1402381","article-title":"Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226","volume":"195","author":"Fuhrman","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib115","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional Anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity","volume":"200","author":"Dixon","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21413-y","article-title":"Implication of TIGIT+ human memory B cells in immune regulation","volume":"12","author":"Hasan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.010_bib117","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni.2850","article-title":"The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions","volume":"15","author":"Chan","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib118","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T\u00a0cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.01.010_bib119","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8(+) T\u00a0cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.01.010_bib120","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2024.01.010_bib121","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","article-title":"Two subsets of stem-like CD8+ memory T\u00a0cell progenitors with distinct fate commitments in humans","volume":"21","author":"Galletti","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.010_bib122","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1084\/jem.20180684","article-title":"High-dimensional single cell analysis identifies stemlike cytotoxic CD8+T cells infiltrating human tumors","volume":"215","author":"Brummelman","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib123","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8\u00a0T Cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.010_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15025-1","article-title":"TIGIT limits immune pathology during viral infections","volume":"11","author":"Schorer","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.010_bib125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121157","article-title":"CD226 opposes TIGIT to disrupt Tregs in melanoma","volume":"3","author":"Fourcade","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2024.01.010_bib126","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124427","article-title":"TIGIT signaling restores suppressor function of Th1 Tregs","volume":"4","author":"Lucca","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2024.01.010_bib127","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.immuni.2024.01.010_bib128","series-title":"Genentech Reports Interim Results for\u00a0Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer","year":"2022"},{"key":"10.1016\/j.immuni.2024.01.010_bib129","article-title":"121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with\/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy","volume":"20","author":"Peled","year":"2023","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.immuni.2024.01.010_bib130","author":"Rudin","year":"2022"},{"key":"10.1016\/j.immuni.2024.01.010_bib131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4010","article-title":"Results from the MORPHEUS-liver study: Phase Ib\/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)","volume":"41","author":"Finn","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.immuni.2024.01.010_bib132","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100003","article-title":"First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions","volume":"6","author":"Ortega-Franco","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.immuni.2024.01.010_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.36_suppl.397600","article-title":"ARC-7: Randomized phase 2 study of domvanalimab\u00a0+ zimberelimab\u00a0\u00b1 etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)","volume":"40","author":"Johnson","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.immuni.2024.01.010_bib135","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.010_bib136","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.010_bib91","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.immuni.2024.01.010_bib92","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/gtc.12247","article-title":"Regulation by gut commensal bacteria of carcinoembryonic antigen-related cell adhesion molecule expression in the intestinal epithelium","volume":"20","author":"Kitamura","year":"2015","journal-title":"Genes Cells"},{"key":"10.1016\/j.immuni.2024.01.010_bib89","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.4049\/jimmunol.1300945","article-title":"The CD226\/CD155 interaction regulates the proinflammatory (Th1\/Th17)\/anti-inflammatory (Th2) balance in humans","volume":"191","author":"Lozano","year":"2013","journal-title":"J.\u00a0Immunol."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:49:41Z","timestamp":1739396981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761324000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1074761324000359"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}